Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and...

Abstract

Using uPA and PAI-1, we have been able to classify about half of the patients with lymph node-negative breast cancer as low risk, for whom adjuvant chemotherapy may be avoided, and half as high risk, who appear to benefit from adjuvant chemotherapy.

Keywords

Plasminogen activatorUrokinaseMedicineBreast cancerOncologyAdjuvant chemotherapyRandomized controlled trialInternal medicineChemotherapyPlasminogen activator inhibitor-1Cancer researchCancer

Affiliated Institutions

Related Publications

National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

Patricia J. Eifel , Jan Axelson , Janitha Costa +11 more

The panel concludes that decisions regarding adjuvant hormonal therapy should be based on the presence of hormone receptor protein in tumor tissues. Adjuvant hormonal therapy sh...

2001 JNCI Journal of the National Cancer I... 894 citations

Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.

P J van Diest , Rob Michalides , L Jannink +5 more

Cyclin D1 overexpression, detected by standard immunohistochemistry, was correlated with other prognostic variables and its prognostic value was evaluated in a group of 148 inva...

1997 PubMed 208 citations

Effect of Antihypertensive Treatment in Patients Having Already Suffered From Stroke

François Gueyffier , Jean‐Pierre Boissel , Florent Boutitie +10 more

Background and Purpose Drug treatment of high blood pressure has been shown to reduce the associated cardiovascular risk. Stroke represents the type of event more strongly linke...

1997 Stroke 247 citations

Publication Info

Year: 2001
Type: article
Volume: 93
Issue: 12
Pages: 913-920
Citations: 435
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

435

OpenAlex

Cite This

APA Style

                            
                                
                                    F. Jänicke, 
                                
                                    A. Prechtl, 
                                
                                    Christoph Thomssen
                                
                                et al.
                            
                            (2001). 
                            Randomized Adjuvant Chemotherapy Trial in High-Risk, Lymph Node-Negative Breast Cancer Patients Identified by Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1. 
                            JNCI Journal of the National Cancer Institute
                            , 93
                            (12)
                            , 913-920.
                            https://doi.org/10.1093/jnci/93.12.913
                        

Identifiers

DOI: 10.1093/jnci/93.12.913